Please assess the completion status of the following clinical trial:

Trial Title: Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed metastatic prostate cancer that is castrate-resistant.~* 2-3 lesions suitable for radiotherapy.~* ECOG Performance status 0-2.~  * Adequate bone marrow, hepatic and renal function~ * At least 4 weeks must have elapsed prior to commencement of idronoxil treatment since prior chemotherapy, investigational drug or biologic therapy~Exclusion Criteria:~* Chemotherapy regimens with delayed toxicity within the last 4 weeks.~* Any situation where the use of suppository therapy is contra-indicated or impractical(eg. chronic diarrhoea, colostomy, ulcerative colitis).~* No concurrent systemic chemotherapy or biologic therapy is allowed.~* Psychiatric disorder or social or geographic situation that would preclude study participation.~* Patient unable to provide consent

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 NOX66 400mg and SBRT (Type: EXPERIMENTAL): Group 1 patients will receive 400mg of Idronoxil (NOX66) suppository (1 suppository) daily from Day 0 (1 day before radiotherapy) until 7 days after completion of radiotherapy. Stereotactic Body Radiation Therapy will be given on Days1-5 (5 fractions). Total treatment course is 13-15 days, depends on whether radiotherapy is given on consecutive days or over the weekend.
- Group 2 NOX66 800mg and SBRT (Type: EXPERIMENTAL): Group 2 patients will receive 800mg of Idronoxil (NOX66) suppository (2 suppositories) daily from Day 0 (1 day before radiotherapy) until 7 days after completion of radiotherapy. Stereotactic Body Radiation Therapy will be given on Days1-5 (5 fractions). Total treatment course is 13-15 days, depends on whether radiotherapy is given on consecutive days or over the weekend.

Based on this trial design, predict the completion outcome and termination type (if applicable).